Compare LYNX & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYNX | KARD |
|---|---|---|
| Founded | 2018 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2026 | 2026 |
| Metric | LYNX | KARD |
|---|---|---|
| Price | $12.10 | $11.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $19.83 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 520.3K | 441.3K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $61.71 | N/A |
| Revenue Next Year | $30.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.75 | $12.23 |
| 52 Week High | $15.50 | $27.00 |
| Indicator | LYNX | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 35.74 |
| Support Level | $10.49 | N/A |
| Resistance Level | $13.74 | $16.26 |
| Average True Range (ATR) | 1.22 | 1.30 |
| MACD | -0.08 | -0.24 |
| Stochastic Oscillator | 47.45 | 0.60 |
Lyntris Inc is a defense technology company that develops connectivity solutions for military applications. Its products consist of interconnected subsystems designed to support defense and military customers in detecting threats, making decisions, and responding to operational requirements across multi-domain environments. The company serves U.S. and allied nation military customers. Its solutions are deployed across three core missions: Maritime Domain Awareness; Air & Missile Defense; and Space ISR & Resilient Communications. Maximum revenue is derived from the Maritime Domain Awareness business, which includes solutions focused on maritime monitoring, tracking and analysis that support government and defense customers in maintaining situational awareness across maritime environments.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.